New Blood Test for Alzheimer’s Disease Now Available in Hong Kong
HONG KONG, March 10, 2026 – Codex Genetics, a precision diagnostics company based in Hong Kong, has announced a collaboration with C2N Diagnostics to bring the PrecivityAD2™ blood test to healthcare professionals across Hong Kong. This innovative technology offers a less invasive method for aiding in the diagnosis of Alzheimer’s disease.
Understanding the PrecivityAD2™ Test
The PrecivityAD2™ test is designed for individuals aged 50 and older who are experiencing cognitive impairment and are undergoing evaluation for Alzheimer’s disease or other causes of cognitive decline. It works by detecting the presence or absence of brain amyloid pathology, a key indicator of Alzheimer’s disease, to support a clinician’s diagnosis.
The test utilizes high-resolution mass spectrometry to measure the plasma amyloid beta (Aβ42/40) ratio and the percentage of phosphorylated tau at threonine-217 (%p-tau217). These measurements are combined using a proprietary algorithm to provide a clear Positive or Negative result, indicating the likelihood of amyloid plaque presence.[1]
Proven Accuracy and Validation
Clinical validation studies have demonstrated the high performance of the PrecivityAD2™ test. Results show 91% accuracy, 90% sensitivity, and 92% specificity when compared to amyloid PET imaging.[2] These findings align with recommendations from the 2025 Alzheimer’s Association Clinical Practice Guidelines for confirmatory blood biomarker tests, which suggest a target of ≥90% accuracy/sensitivity/specificity.[3]
A 2024 study published in the Journal of the American Medical Association (JAMA) highlighted the test’s ability to improve diagnostic accuracy in primary care settings, where many patients initially seek answers regarding memory loss. The study showed an accuracy of over 90% at a single cutoff point compared to cerebrospinal fluid (CSF) analysis or amyloid PET analysis.[4]
Addressing a Growing Public Health Concern
Alzheimer’s disease is an increasing public health concern in Hong Kong and throughout Asia, driven by aging populations. Epidemiological data indicates that approximately 20% of community-dwelling older adults in Hong Kong experience mild neurocognitive impairment, and 7.4% are affected by major neurocognitive disorders (dementia), with prevalence increasing with age.[5]
Statements from Company Leaders
“Our collaboration with C2N reinforces Codex Genetics’ commitment to advancing precision medicine and improving access to cutting-edge diagnostic technologies in Hong Kong and the region,” said Dr. Aldrin Yim, Co-Founder of Codex Genetics. “Alzheimer’s disease places a significant burden on patients, caregivers, and healthcare systems. The PrecivityAD2™ test offers a practical, reliable, and less invasive alternative to PET scans or lumbar punctures, enabling clinicians to make earlier and more informed decisions in both public and private settings.”
“We are pleased to partner with Codex Genetics to expand access to the PrecivityAD2™ test in Hong Kong,” said Dr. Joel Braunstein, CEO of C2N. “Codex Genetics’ proven capabilities in precision diagnostics make them an ideal partner to support clinicians and patients seeking an accessible, high-quality blood test for Alzheimer’s disease evaluation.”
Accessing the PrecivityAD2™ Test in Hong Kong
The PrecivityAD2™ blood test provides a convenient and accurate option, particularly in situations where PET imaging or cerebrospinal fluid testing may be limited.
For more information or to order the test, please contact:
- WhatsApp: (+852) 9837 1345
- Phone: (+852) 3008 2560
- Email: support@codexgenetics.com
Additional information can be found at www.precivityad.com and www.codexgenetics.com.
References
- Meyer et al. Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid. Alz &. Dementia, 2024.
- Coppinger, J., et al. Independent validation of the PrecivityAD2TM blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment. Npj Dementia, 2025.
- Palmquist et al., Alzheimer’s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings. Alz & Dementia, 2025.
- Palmqvist et al., Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care. JAMA, 2024. doi:10.1001/jama.2024.13855
- HKSAR Department of Health, Elderly Health Service (Dementia resources). Chinese University of Hong Kong (CUHK) epidemiological data.